Phastar Achieves B Rating in CDP, Strengthening Our Leadership in Corporate Responsibility 

2 minute read

Published: March 24th, 2025

As we celebrate B Corp Month, Phastar reaffirms its commitment to responsible business practices that drive real impact. We continue to drive sustainability through initiatives such as our net-zero targets, pro bono biometrics support for charities, and ESG-driven clinical trial solutions. 

Additionally, we are proud to announce that Phastar has improved its CDP sustainability score, achieving a commendable B rating this year. This progress reflects our commitment to environmental transparency and action, recognizing the measurable steps we have taken to enhance emissions management, climate risk assessment, and sustainability initiatives. 

CDP is a global non-profit that runs the world’s only independent environmental disclosure system for companies to manage their environmental impacts. Achieving a B rating places Phastar in the Management band, highlighting our dedication to integrating climate considerations into our operations and decision-making. 

This recognition reinforces our mission to lead the CRO industry in responsible business practices that benefit our communities, employees, clients, and the environment. 

This B Corp Month, we celebrate the businesses proving that corporate responsibility isn’t just an ideal—it’s a necessity. We’re proud to be leading the charge in the CRO space, showing that scientific excellence and ethical leadership go hand in hand. 

Related articles

Advancing Early-Phase Trials: Emerging Practices and Insights 

Advancing Early-Phase Trials: Emerging Practices and Insights 

January 27th, 2026 6 minute read

The landscape of early-phase clinical research continues to evolve rapidly. As new therapeutic modalities emerge...

Expert Opinion on FDA Recommendations on Bayesian Methods for Drug Development

Expert Opinion on FDA Recommendations on Bayesian Methods for Drug Development

January 27th, 2026 6 minute read

On the 12th January  2026 the FDA brought out recommended guidance on the use of Bayesian me...

Understanding Key Statistical Concepts in Early-Phase Clinical Trials 

Understanding Key Statistical Concepts in Early-Phase Clinical Trials 

January 20th, 2026 5 minute read

Statistics sit at the heart of every early-phase clinical trial. From dose escalation to determining the Ma...